Download the press release in PDF format - Aptar
Download the press release in PDF format - Aptar
Download the press release in PDF format - Aptar
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
PRESCRIPTION DIVISION<br />
PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE<br />
The VP7 spray pump – mak<strong>in</strong>g drug delivery easier and safer while improv<strong>in</strong>g patient comfort<br />
<strong>Aptar</strong> Pharma’s high-performance VP7 spray pump is widely used <strong>in</strong> drug delivery for both systemic<br />
and local treatment via <strong>the</strong> nasal and <strong>the</strong> buccal routes. For Sativex ® , GW Pharmaceuticals selected<br />
<strong>the</strong> VP7 spray pump fitted with a specific buccal actuator of ergonomic design that is comfortable to<br />
use by <strong>the</strong> patient. The VP7 platform is recognized globally for its comfort of use by patients as well as<br />
for its robustness coupled with outstand<strong>in</strong>g dose accuracy and spray performance.<br />
“GW Pharmaceuticals is a key client for <strong>Aptar</strong> Pharma, and we are proud that our collaboration<br />
has now led to <strong>the</strong> launch of <strong>the</strong>ir important new medic<strong>in</strong>e for patients suffer<strong>in</strong>g from multiple<br />
sclerosis.” said Pierre Carlotti, Vice President Market<strong>in</strong>g and Communication for <strong>Aptar</strong> Pharma<br />
Prescription Division.<br />
Sativex ® is a registered trademark of GW Pharmaceuticals.<br />
For more <strong>in</strong><strong>format</strong>ion about Sativex ® , visit http://www.gwpharm.com/Sativex.aspx<br />
Sativex ® is <strong>in</strong>dicated as treatment for symptom improvement <strong>in</strong> patients with moderate to severe<br />
spasticity due to multiple sclerosis (MS) who have not responded adequately to o<strong>the</strong>r anti-spasticity<br />
medication and who demonstrate cl<strong>in</strong>ically significant improvement <strong>in</strong> spasticity related symptoms<br />
dur<strong>in</strong>g an <strong>in</strong>itial trial of <strong>the</strong>rapy.<br />
About <strong>Aptar</strong> Pharma<br />
<strong>Aptar</strong> Pharma is part of <strong>the</strong> <strong>Aptar</strong>group family of companies, along with <strong>Aptar</strong> Beauty + Home and <strong>Aptar</strong> Food + Beverage. We create<br />
<strong>in</strong>novative drug delivery systems that meet <strong>the</strong> evolv<strong>in</strong>g needs of biotechnology, healthcare and pharmaceutical companies around <strong>the</strong><br />
world. We provide our customers with a wide range of delivery technologies and analytical services backed by years of proven expertise.<br />
<strong>Aptar</strong>group (NYSE: ATR) is headquartered <strong>in</strong> <strong>the</strong> US and has manufactur<strong>in</strong>g sites <strong>in</strong> North America, Europe, Asia and South America.<br />
For more <strong>in</strong><strong>format</strong>ion, visit http://www.aptar.com/pharma<br />
Press Contacts<br />
Elisa Eschylle, Events and Press relations manager<br />
Tel.: +33 (0)1 39 17 20 41 - Email : elisa.eschylle@aptar.com<br />
Marion Baschet Vernet , Press attaché<br />
Tel.: +44 (0)797 609 41 00 - Email : mbvernet@gmail.com<br />
Deliver<strong>in</strong>g solutions, shap<strong>in</strong>g <strong>the</strong> future.<br />
2/2
Change language